Blue Cross Blue Shield of Rhode IslandCommercial · Billing Codes · Physician / Facility · RI · Emergency Medicine, Critical Care, Infectious Disease +2 moreMedium impact
COVID-19 Monoclonal Antibody Treatment and Antiviral IV Medications
Effective date
May 1, 2022
Identified
Jun 19, 2026
Summary
BCBS Rhode Island has added new billing codes for COVID-19 monoclonal antibody treatments and antiviral IV medications. The policy includes several HCPCS codes (M0220, M0221, M0222, M0223) and HCPCS Q codes (Q0220, Q0221, Q0222) along with one J code (J0248) that were added throughout 2022.
Get alerts when payers change rules like this one
We check Blue Cross Blue Shield of Rhode Island and other payers every day and email you when a change matches your specialty and state.
01Billing team should verify these COVID-19 treatment codes are active in billing system and reference the full payment policy for specific coverage details and billing requirements.
02Update encounter forms to include these codes for COVID-19 monoclonal antibody and antiviral IV treatments.
Codes mentioned
M0220M0221Q0220J0248Q0222M0222M0223Q0221
Original notice
COVID-19 Monoclonal Antibody Treatment and Antiviral IV Medications
bcbsri.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.